drugset

drugset / Trial / NCT06057454

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

NCT06057454 ↗

Phase 1 Completed 9 enrolled Rise Therapeutics LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients

Timeline

Start: 2023-12-05
Primary completion: 2025-11-05
Completion: 2025-11-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	R-5280	Unknown	—	Oral

Indications